AVPR1B Antikörper (PE-Cy7)

Produktnummer ABIN1428259

Dieses Kaninchen Polyklonal-Antikörper erkennt spezifisch AVPR1B in WB. Er zeigt eine Reaktivität gegenüber Human, Ratte, Maus, Hund, Rind (Kuh) und Schwein.

Kurzübersicht für AVPR1B Antikörper (PE-Cy7) (ABIN1428259)

Target: AVPR1B (Arginine Vasopressin Receptor 1B (AVPR1B))

Reaktivität: Human, Ratte, Maus, Hund, Rind (Kuh), Schwein

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser AVPR1B Antikörper ist konjugiert mit PE-Cy7

Applikation: Western Blotting (WB)

Produktdetails anti-AVPR1B Antikörper (PE-Cy7)

Homologie: Human,Mouse,Rat,Dog,Cow,Pig,Horse

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human AVP Receptor V3

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: FCM(1:100-500)
Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Haltbarkeit: 12 months

Details zu AVPR1B

Target: AVPR1B (Arginine Vasopressin Receptor 1B (AVPR1B))

Andere Bezeichnung: AVPR1B/AVP Receptor V3

Hintergrund:

Synonyms: Antidiuretic hormone receptor 1b, Arginine vasopressin receptor 1B, Arginine vasopressin receptor 3, AVPR V1b, AVPR V3, Avpr1b, AVPR3, Pituitary vasopressin receptor 3, V1bR, V1BR_HUMAN, Vasopressin V1b receptor, Vasopressin V3 receptor, VPR3.

Background: Vasopressin (AVP), the antidiuretic hormone, is a cyclic nonpeptide that is involved in the regulation of body fluid osmolality (1-3). AVP mediates its effects through a family of G-protein coupled receptors, the vasopressin receptors type V1a, V2 and V3 (also designated V1b) (1,2). The AVP receptor V1a is responsible for several functions, including blood vessel constriction, liver glycogenolysis and platelet adhesion (3). It is detected as a full length protein and a shorter protein, which results from proteolytic cleavage of its amino terminus (4). The V1a receptor is coupled to Gq/11 protein, which increases the intracellular calcium concentration (3). The human AVP receptor V2 gene maps to chromosome Xq28 and is expressed in lung and kidney (5,6). Mutations in the V2 receptor result in nephrogenic diabetes insipidus (NDI), a rare X-linked disorder characterized by the inability of the kidney to concentrate urine in response to AVP (5,7). The AVP Receptor V2 activates the Gs protein and the cyclic AMP second messenger system (7). The AVP receptor V3 is preferentially expressed in the pituitary and stimulates the release of adrenocorticotropic hormone (ACTH) in response to AVP by mobilizing intracellular calcium stores (8). AVP receptor antagonists may have potential therapeutic effects in hypertension, congestive heart failure, nephrotic syndrome and ACTH-secreting tumors (2).

Molekulargewicht: 47kDa

Pathways: Regulation of Systemic Arterial Blood Pressure by Hormones